Background: The rise within the variety of most cancers circumstances and the evolution of most cancers care administration have turn out to be a big downside for the French well being care system, thereby making affected person empowerment as a protracted sought-after purpose in continual pathologies. The implementation of an activation measure through the Affected person Activation Measure-13 merchandise (PAM-13) in the midst of most cancers care can probably spotlight the affected person’s wants, with nursing care adapting accordingly.

Goal: The goals of this PARACT (PARAmedical Interventions on Affected person ACTivation) multicentric research have been as follows: (1) consider the implementation of PAM-13 in oncology nursing practices in 5 complete most cancers facilities, (2) determine the obstacles and facilitators to the implementation of PAM-13, and (3) produce suggestions for the dissemination of such interventions in different complete most cancers facilities.

Strategies: This research will comply with the “Attain, Effectiveness, Adoption, Implementation, and Upkeep” framework and can consist of three phases. First, a strong preimplementation evaluation will probably be performed utilizing the Theoretical Domains Framework (TDF) linked to the “Functionality, Alternative, Motivation, and Conduct” mannequin to determine the obstacles and facilitators to implementing new nursing practices in every context. Then, utilizing the Conduct Change Wheel, we are going to personalize a technique for implementing the PAM-13, relying on the specificities of every context, to encourage acceptability by the nursing employees concerned within the mission. This evaluation will probably be carried out through a qualitative research by way of semistructured interviews.

Second, the affected person will probably be included within the research for 12 months, throughout which the affected person care pathway will probably be studied, significantly to gather all related contacts of oncology nurses and different well being professionals concerned within the pathway. The axes of nursing care may even be collected. The first purpose is to implement PAM-13. Secondary elements to be measured are the affected person’s nervousness stage, high quality of life, and well being literacy stage. The oncology nurses will probably be liable for finishing the questionnaires when the affected person is on the hospital for his/her intravenous chemotherapy/immunotherapy remedy. The questionnaires will probably be accomplished thrice in a 12 months: (1) on the time of the affected person’s enrollment, (2) at 6 months, and (3) at 12 months. Third, a postimplementation evaluation will probably be carried out by way of semistructured interviews utilizing the TDF to research the implementation issues at every website.

Outcomes: This research was supported by a grant from the French Ministry of Well being (PHRIP PARACT 2016-0405) and the Lucien Neuwirth Institute of Cancerology of Saint-Etienne, France. Knowledge assortment for this research is ongoing.

Conclusions: This research would enhance the carried out focused nursing interventions in most cancers facilities so {that a} affected person is obtainable a customized most cancers care pathway. Moreover, measuring the extent of activation and the implementation of measures meant to extend such activation may represent a big benefit in decreasing social well being inequalities.

In lots of cancers, tumour development is related to elevated tissue stiffness. But, the mechanisms associating tissue stiffness with tumorigenesis and malignant transformation are unclear. Right here we present that in gastric most cancers cells, the stiffness of the extracellular matrix reversibly regulates the DNA methylation of the promoter area of the mechanosensitive Sure-associated protein (YAP). Reciprocal interactions between YAP and the DNA methylation inhibitors GRHL2, TET2 and KMT2A may cause hypomethylation of the YAP promoter and stiffness-induced oncogenic activation of YAP.

Gastrointestinal Cancer Antigen (CA 19-9), antigen grade
CA1991-N-10	Alpha Diagnostics	10 KU	EUR 529

Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit
PRB-5069	Cell Biolabs	96 assays	EUR 572

Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit
PRB-5069-5	Cell Biolabs	5 x 96 assays	EUR 2283

Cancer Antigen 15-3 MUC 1 Antigen (Human Milk)
VAng-Cr3871-10kU	Creative Biolabs	10 kU	EUR 421
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Milk. The purity is detected by salt extraction and delipidization following high speed centrifugation. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2.

Paraffin Tissue Section - Human Breast Tumor: Lobular carcinoma
T2235086-3	Biochain	5 slides	EUR 257
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Breast Cancer-Associated Antigen BRCAA1 (BRCAA1) Antibody
20-abx148333	Abbexa	EUR 425.00 EUR 342.00	100 ug 50 ug

Cancer Antigen 15-3 MUC 1 Antigen (Human Ascites Fluid)
VAng-Cr3872-10kU	Creative Biolabs	10 kU	EUR 1136
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Ascites Fluid.

Cancer Antigen CA 15-3 Protein (Human Fluids)
VAng-Wyb8628-inquire	Creative Biolabs	inquire	Ask for price
Description: CA 15-3 (Breast Cancer Antigen), Cancer antigen from Human Fluids, 12.240 kU/mL.

Cancer Antigen CA 15-3 Protein (Human Milk)
VAng-Wyb8631-inquire	Creative Biolabs	inquire	Ask for price
Description: CA 15-3 (Breast Cancer Antigen), Antigen Grade, Cancer antigen from Human Milk, 33.0 kIU/mL.

Paraffin Tissue Section - Human Brain Tumor: Astrocytoma Grade III
T2235035-3	Biochain	5 slides	EUR 257
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Cancer Antigen 15-3 (CA15-3) (human) ELISA Kit
K4804-100	Biovision	100 assays	EUR 834
Description: Sensitive, Colorimetric Assay

Breast Cancer Exosome
P141-BR	101Bio	-	Ask for price

Human Cancer PrimaCell4: Breast Tumor Cells Growth Medium
9-46027	CHI Scientific	5 x 100 ml	Ask for price

Proteinase K, Recombinant, Standard Grade
9250-100	Biovision		EUR 104

Proteinase K, Recombinant, Standard Grade
9250-10G	Biovision		EUR 3856

Proteinase K, Recombinant, Standard Grade
9250-1G	Biovision		EUR 457

Proteinase K, Recombinant, Standard Grade
9250-500	Biovision		EUR 262

Proteinase K, Recombinant, Standard Grade
9251-100	Biovision		EUR 1055

Proteinase K, Recombinant, Standard Grade
9251-25	Biovision		EUR 294

Proteinase K, Recombinant, Standard Grade
9251-5	Biovision		EUR 120

Fluorescent Exosome Standard (Urine )
ESF-15	Creative Biolabs	100 µg	EUR 1723
Description: Fluorescent exosomes are labeled with green dye, which offer a stable fluorescent labeling.

Human Cancer Tissue Preparation Buffer 4: Breast Tumor Cells
9-80027	CHI Scientific	1 x 100 ml	Ask for price

Breast Cancer Exosome RNA
P241-BR	101Bio	-	Ask for price

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit
RD-CA15-3-Hu-48Tests	Reddot Biotech	48 Tests	EUR 478

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit
RD-CA15-3-Hu-96Tests	Reddot Biotech	96 Tests	EUR 662

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit
DLR-CA15-3-Hu-48T	DL Develop	48T	EUR 479
Description: A sandwich quantitative ELISA assay kit for detection of Human Carbohydrate Antigen 15-3 (CA15-3) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit
DLR-CA15-3-Hu-96T	DL Develop	96T	EUR 621
Description: A sandwich quantitative ELISA assay kit for detection of Human Carbohydrate Antigen 15-3 (CA15-3) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit
RDR-CA15-3-Hu-48Tests	Reddot Biotech	48 Tests	EUR 500

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit
RDR-CA15-3-Hu-96Tests	Reddot Biotech	96 Tests	EUR 692

Polystyrene Particle Size Standard
PPS-3	Spherotech	mL	EUR 127
Description: Please reffer to the technical data sheet for more detail information for this item. Our dedicated team would be happy to assist you via live chat, email or phone.

Inactivated MuV Grade 3 Antigen
VAng-Lsx0411-inquire	Creative Biolabs	inquire	Ask for price
Description: MuV grade 3, native protein.

Inactivated CMV Grade 3 Antigen
VAng-Lsx0038-1mg	Creative Biolabs	1 mg	EUR 2086
Description: CMV Grade 3, natural protein.

Inactivated Rotavirus Grade 3 Antigen
VAng-Lsx0469-inquire	Creative Biolabs	inquire	Ask for price
Description: Rotavirus Grade 3, native virus.

Inactivated RuV Grade 3 Antigen
VAng-Lsx0476-1mL	Creative Biolabs	1 mL	EUR 395
Description: RuV Grade 3, natural protein.

Breast Tumor Lysate
1323	ProSci	0.1 mg	EUR 254
Description: Breast tumor lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

CA 15-3, Human Breast Adenocarcinoma
P1435-1	Biovision		EUR 109

CA 15-3, Human Breast Adenocarcinoma
P1435-5	Biovision		EUR 240

99445-15 DCT 15 X 85MM
99445-15	CORNING	250/pk	EUR 97
Description: Disposable Culture Tubes; DCT's, CGW

Cancer Antigen 242 Antigen
VAng-Cr3876-10kU	Creative Biolabs	10 kU	EUR 421
Description: Cancer Antigen 242 Antigen, Host/Source: Metastatic Liver. The purity is detected by gel filtration.

Cancer Antigen 50 Antigen
VAng-Cr3877-50kU	Creative Biolabs	50 kU	EUR 5535
Description: Cancer Antigen 50 Antigen, Host/Source: Human Cell Culture. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2.

Breast Cancer Metastasis Suppressor 1
PR27265	Neuromics	2 ug	EUR 191

Inactivated PIV-3 Grade 2 Antigen
VAng-Wyb3637-1mL	Creative Biolabs	1 mL	EUR 1136
Description: Parainfluenza virus type 3 (strain C243) Grade 2, natural antigen

Inactivated HSV-2 Grade 3 Antigen
VAng-Lsx0302-1mg	Creative Biolabs	1 mg	EUR 1489
Description: HSV Type 2 Grade III, native antigen.

Human CA15-3 Antigen Grade Protein
abx060972-250kU	Abbexa	250 kU	EUR 1984

Inactivated HSV-1 Grade 3 Antigen
VAng-Lsx0293-1mg	Creative Biolabs	1 mg	EUR 1489
Description: HSV Type 1 Grade III, native antigen.

Human Breast Tumor lysate
HTL-1323	Alpha Diagnostics	1 mg	EUR 773

Breast Tumor Kinase Antibody
AF4768	Affbiotech	200ul	EUR 376
Description: Breast Tumor Kinase Antibody detects endogenous levels of Breast Tumor Kinase.

Breast Tumor Kinase antibody
70R-31875	Fitzgerald	100 ug	EUR 327
Description: Rabbit polyclonal Breast Tumor Kinase antibody

Breast Tumor Kinase antibody
70R-33385	Fitzgerald	100 ug	EUR 327
Description: Rabbit polyclonal Breast Tumor Kinase antibody

Breast Tissue Lysate (Tumor)
1713-01	ProSci	0.1 mg	EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)
1713-02	ProSci	0.1 mg	EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)
1714-01	ProSci	0.1 mg	EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)
1714-02	ProSci	0.1 mg	EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)
1714-03	ProSci	0.1 mg	EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)
1714-04	ProSci	0.1 mg	EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)
1714-05	ProSci	0.1 mg	EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)
1714-06	ProSci	0.1 mg	EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)
1714-07	ProSci	0.1 mg	EUR 280.25
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Membrane Tumor Lysate
XBL-10499	ProSci	0.1 mg	EUR 626.75
Description: Human breast tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human breast tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated breast tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated breast tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

Vitamin A Reference Standard (USP grade powder)
51R-U716002	Fitzgerald	10 pack	EUR 516
Description: Vitamin A Reference Standard (USP grade powder) chemical reference substance

CEA Antigen Grade Protein
abx060976-05mg	Abbexa	0.5 mg	EUR 968

CEA Antigen Grade Protein
abx060977-1mg	Abbexa	1 mg	EUR 1692

Prostate Specific Antigen Std Grade Antigen
VAng-Cr3891-1mg	Creative Biolabs	1 mg	EUR 504
Description: Prostate Specific Antigen Std Grade Antigen, Host/Source: Human Seminal Fluid. The purity is detected by salt precipitation.

Cancer Antigen 72-4 Antigen
VAng-Cr3878-10kU	Creative Biolabs	10 kU	EUR 421
Description: Cancer Antigen 72-4 Antigen, Host/Source: Metastatic Liver. The purity is ~65% by SDS-PAGE. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2.

Recombinant Breast Cancer Anti-Estrogen Resistance 3 (BCAR3)
4-RPG768Hu01	Cloud-Clone	EUR 501.41 EUR 237.00 EUR 1605.28 EUR 601.76 EUR 1103.52 EUR 398.00 EUR 3863.20	100 ug 10ug 1 mg 200 ug 500 ug 50ug 5 mg
Description: Recombinant Human Breast Cancer Anti-Estrogen Resistance 3 expressed in: E.coli

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody
20-abx129227	Abbexa	EUR 425.00 EUR 133.00 EUR 1205.00 EUR 578.00 EUR 328.00	100 ug 10 ug 1 mg 200 ug 50 ug

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody
20-abx133658	Abbexa	EUR 300.00 EUR 439.00 EUR 189.00	100 ul 200 ul 30 ul

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody
20-abx013807	Abbexa	EUR 314.00 EUR 98.00 EUR 398.00 EUR 495.00	100 ug 10 ug 200 ug 300 µg

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody
abx025588-400ul	Abbexa	400 ul	EUR 523

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody
abx025588-80l	Abbexa	80 µl	EUR 286

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody
20-abx171475	Abbexa	EUR 857.00 EUR 439.00	1 mg 200 ug

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody
20-abx324781	Abbexa	EUR 314.00 EUR 244.00	100 ug 50 ug

Anti-Breast Cancer Resistance Protein antibody
STJ16100903	St John's Laboratory	1 mL	EUR 478

Anti-Breast Cancer Resistance Protein antibody
STJ16100916	St John's Laboratory	1 mL	EUR 478

Breast Cancer Anti-Estrogen Resistance 1
PR27245	Neuromics	2 ug	EUR 191

Breast Cancer Metastasis Suppressor 1 Protein
20-abx263402	Abbexa	EUR 1609.00 EUR 328.00 EUR 230.00	100 ug 10 ug 2 µg

Autobioluminescent Human Breast Cancer Cells (MCF7)
ASE-5903	Applied StemCell	1 ml	EUR 2075
Description: 6 month

Autobioluminescent Human Breast Cancer Cells (T47D)
ASE-5904	Applied StemCell	1 ml	EUR 2075
Description: 6 month

Human Breast Cancer Signaling Primer Library
HBRCA-I	Real Time Primers	1 set	EUR 548

anti-Breast cancer suppressor candidate 1
YF-PA12974	Abfrontier	50 ul	EUR 363
Description: Mouse polyclonal to Breast cancer suppressor candidate 1

anti-Breast cancer suppressor candidate 1
YF-PA12975	Abfrontier	50 ug	EUR 363
Description: Mouse polyclonal to Breast cancer suppressor candidate 1

anti-Breast cancer suppressor candidate 1
YF-PA24096	Abfrontier	50 ul	EUR 334
Description: Mouse polyclonal to Breast cancer suppressor candidate 1

Human Cancer Antigen CA15-3 Protein
abx060965-50kU	Abbexa	50 kU	EUR 2625

Inactivated MuV Grade 3 Antigen (Strain Enders)
VAng-0619Lsx-inquire	Creative Biolabs	inquire	Ask for price
Description: MuV (Strain Enders) grade 3, native protein. 0.45 mg/mL.

9998 SCREW CAP 415/15
9998-15	CORNING	288/pk	EUR 198
Description: General Apparatus; Stoppers

Breast Tumor Tissue Array - 16 cases of breast cancer, each in duplicates, paired with adjacent normal tissues
Z7020007	Biochain	5 slides	EUR 1381
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Standard grade heat shock BSA powder, pH 7
BAH62-0050	Equitech	50gm	EUR 257.4

Standard grade heat shock BSA powder, pH 7
BAH62-0100	Equitech	100gm	EUR 323.7

Standard grade heat shock BSA powder, pH 7
BAH62-0500	Equitech	500gm	EUR 426.4

Standard grade heat shock BSA powder, pH 7
BAH62-1000	Equitech	1KG	Ask for price

Standard grade heat shock BSA powder, pH 7
BAH62-10000	Equitech	10KG	Ask for price

Standard grade heat shock BSA powder, pH 5.2
BAH63-0050	Equitech	50gm	EUR 257.4

Standard grade heat shock BSA powder, pH 5.2
BAH63-0100	Equitech	100gm	EUR 323.7

Standard grade heat shock BSA powder, pH 5.2
BAH63-0500	Equitech	500gm	EUR 426.4

Standard grade heat shock BSA powder, pH 5.2
BAH63-1000	Equitech	1KG	Ask for price

Standard grade heat shock BSA powder, pH 5.2
BAH63-10000	Equitech	10KG	Ask for price

Cancer Antigen CEA Antigen (Human Fluids)
VAng-Wyb8644-inquire	Creative Biolabs	inquire	Ask for price
Description: Carcinoembryonic Antigen, Calibrator Grade, Cancer antigen from Human Fluids, 1.13 mg/mL.

Cancer Antigen 125 Antigen (Human Adenocarcinoma)
VAng-Cr3868-10kU	Creative Biolabs	10 kU	EUR 421
Description: Cancer Antigen 125 Antigen, Host/Source: Human Adenocarcinoma. The purity is detected by salt extraction and chromatography.

Direct alteration of extracellular cues through in situ matrix softening reversed YAP exercise and the epigenetic program. Our findings recommend that epigenetic reprogramming of the mechanophysical properties of the extracellular microenvironment of stable tumours might symbolize a therapeutic technique for the inhibition of most cancers development.